Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, robust 4.1 percent annual growth in the renal cell carcinoma drug market will be driven primarily by the uptake of GlaxoSmithKline's Votrient/Patorma, the launches of premium-priced emerging therapies and an increase in diagnosed incidence and treatment rates.

The Pharmacor 2010 findings from the topic entitled Renal Cell Carcinoma reveal that significant uptake of the angiogenesis inhibitor Votrient/Patorma will be driven by its use in treating advanced renal cell carcinoma, particularly in the first-line setting. As a result, Votrient/Patorma will become the market leader and will garner sales of nearly $630 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

"In 2009, angiogenesis inhibitors captured more than three-quarters of the renal cell carcinoma drug market, with Pfizer's Sutent accounting for 61 percent of sales in this class," said Decision Resources Analyst Karen Pomeranz, Ph.D. "Angiogenesis inhibitors will continue to dominate this space during our forecast period, capturing nearly 90 percent of the market in 2019. However, in 2019, sales of Sutent will be significantly reduced, owing mainly to the robust uptake of Votrient/Patorma."

The Pharmacor 2010 findings also reveal that the emergence of two targeted agents -- Pfizer's axitinib and Aveo Pharmaceuticals' tivozanib -- will also penetrate this increasingly crowded market. Combined, these two agents will garner nearly one-third of sales in the renal cell carcinoma drug market in 2019.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources, Inc.   Christopher Comfort   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, Inc., +1-781-296-2597,

The Uptake of Two Emerging Agents from Forest/AstraZeneca/Takeda and Trius Will Drive the MRSA Drug Market to Increase from $631 Million in 2009 to $752 Million in 2019

View Now